These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

368 related articles for article (PubMed ID: 25531693)

  • 1. Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients.
    Cripe TP; Ngo MC; Geller JI; Louis CU; Currier MA; Racadio JM; Towbin AJ; Rooney CM; Pelusio A; Moon A; Hwang TH; Burke JM; Bell JC; Kirn DH; Breitbach CJ
    Mol Ther; 2015 Mar; 23(3):602-8. PubMed ID: 25531693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer.
    Park SH; Breitbach CJ; Lee J; Park JO; Lim HY; Kang WK; Moon A; Mun JH; Sommermann EM; Maruri Avidal L; Patt R; Pelusio A; Burke J; Hwang TH; Kirn D; Park YS
    Mol Ther; 2015 Sep; 23(9):1532-40. PubMed ID: 26073886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oncolytic and immunotherapeutic vaccinia induces antibody-mediated complement-dependent cancer cell lysis in humans.
    Kim MK; Breitbach CJ; Moon A; Heo J; Lee YK; Cho M; Lee JW; Kim SG; Kang DH; Bell JC; Park BH; Kirn DH; Hwang TH
    Sci Transl Med; 2013 May; 5(185):185ra63. PubMed ID: 23677592
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase 2, Open-Label, Randomized Study of Pexa-Vec (JX-594) Administered by Intratumoral Injection in Patients with Unresectable Primary Hepatocellular Carcinoma.
    Breitbach CJ; Moon A; Burke J; Hwang TH; Kirn DH
    Methods Mol Biol; 2015; 1317():343-57. PubMed ID: 26072416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The emerging therapeutic potential of the oncolytic immunotherapeutic Pexa-Vec (JX-594).
    Breitbach CJ; Bell JC; Hwang TH; Kirn DH; Burke J
    Oncolytic Virother; 2015; 4():25-31. PubMed ID: 27512667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer.
    Heo J; Reid T; Ruo L; Breitbach CJ; Rose S; Bloomston M; Cho M; Lim HY; Chung HC; Kim CW; Burke J; Lencioni R; Hickman T; Moon A; Lee YS; Kim MK; Daneshmand M; Dubois K; Longpre L; Ngo M; Rooney C; Bell JC; Rhee BG; Patt R; Hwang TH; Kirn DH
    Nat Med; 2013 Mar; 19(3):329-36. PubMed ID: 23396206
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial.
    Park BH; Hwang T; Liu TC; Sze DY; Kim JS; Kwon HC; Oh SY; Han SY; Yoon JH; Hong SH; Moon A; Speth K; Park C; Ahn YJ; Daneshmand M; Rhee BG; Pinedo HM; Bell JC; Kirn DH
    Lancet Oncol; 2008 Jun; 9(6):533-42. PubMed ID: 18495536
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients.
    Samson A; West EJ; Carmichael J; Scott KJ; Turnbull S; Kuszlewicz B; Dave RV; Peckham-Cooper A; Tidswell E; Kingston J; Johnpulle M; da Silva B; Jennings VA; Bendjama K; Stojkowitz N; Lusky M; Prasad KR; Toogood GJ; Auer R; Bell J; Twelves CJ; Harrington KJ; Vile RG; Pandha H; Errington-Mais F; Ralph C; Newton DJ; Anthoney A; Melcher AA; Collinson F
    Cancer Immunol Res; 2022 Jun; 10(6):745-756. PubMed ID: 35439304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccinia-based oncolytic immunotherapy Pexastimogene Devacirepvec in patients with advanced hepatocellular carcinoma after sorafenib failure: a randomized multicenter Phase IIb trial (TRAVERSE).
    Moehler M; Heo J; Lee HC; Tak WY; Chao Y; Paik SW; Yim HJ; Byun KS; Baron A; Ungerechts G; Jonker D; Ruo L; Cho M; Kaubisch A; Wege H; Merle P; Ebert O; Habersetzer F; Blanc JF; Rosmorduc O; Lencioni R; Patt R; Leen AM; Foerster F; Homerin M; Stojkowitz N; Lusky M; Limacher JM; Hennequi M; Gaspar N; McFadden B; De Silva N; Shen D; Pelusio A; Kirn DH; Breitbach CJ; Burke JM
    Oncoimmunology; 2019; 8(8):1615817. PubMed ID: 31413923
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression profiling of hematologic malignant cell lines resistant to oncolytic virus treatment.
    Lee NH; Kim M; Oh SY; Kim SG; Kwon HC; Hwang TH
    Oncotarget; 2017 Jan; 8(1):1213-1225. PubMed ID: 27901484
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade.
    Chon HJ; Lee WS; Yang H; Kong SJ; Lee NK; Moon ES; Choi J; Han EC; Kim JH; Ahn JB; Kim JH; Kim C
    Clin Cancer Res; 2019 Mar; 25(5):1612-1623. PubMed ID: 30538109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9.
    Deng L; Fan J; Guo M; Huang B
    Cancer Lett; 2016 Mar; 372(2):251-7. PubMed ID: 26803055
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PHOCUS: A Phase 3, Randomized, Open-Label Study of Sequential Treatment with Pexa-Vec (JX-594) and Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
    Abou-Alfa GK; Galle PR; Chao Y; Erinjeri J; Heo J; Borad MJ; Luca A; Burke J; Pelusio A; Agathon D; Lusky M; Breitbach C; Qin S; Gane E
    Liver Cancer; 2024 Jun; 13(3):248-264. PubMed ID: 38756145
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Isolation of vaccinia JX594 from pustules following therapy for hepatocellular carcinoma.
    Kung CH; Kuo SC; Chen TL; Weng WS
    BMC Cancer; 2015 Oct; 15():704. PubMed ID: 26471278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques.
    Evgin L; Acuna SA; Tanese de Souza C; Marguerie M; Lemay CG; Ilkow CS; Findlay CS; Falls T; Parato KA; Hanwell D; Goldstein A; Lopez R; Lafrance S; Breitbach CJ; Kirn D; Atkins H; Auer RC; Thurman JM; Stahl GL; Lambris JD; Bell JC; McCart JA
    Mol Ther; 2015 Jun; 23(6):1066-1076. PubMed ID: 25807289
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics.
    Guo ZS; Lu B; Guo Z; Giehl E; Feist M; Dai E; Liu W; Storkus WJ; He Y; Liu Z; Bartlett DL
    J Immunother Cancer; 2019 Jan; 7(1):6. PubMed ID: 30626434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pexa-Vec double agent engineered vaccinia: oncolytic and active immunotherapeutic.
    Breitbach CJ; Parato K; Burke J; Hwang TH; Bell JC; Kirn DH
    Curr Opin Virol; 2015 Aug; 13():49-54. PubMed ID: 25900822
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oncolytic virus therapy: A new era of cancer treatment at dawn.
    Fukuhara H; Ino Y; Todo T
    Cancer Sci; 2016 Oct; 107(10):1373-1379. PubMed ID: 27486853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma.
    Lun X; Chan J; Zhou H; Sun B; Kelly JJ; Stechishin OO; Bell JC; Parato K; Hu K; Vaillant D; Wang J; Liu TC; Breitbach C; Kirn D; Senger DL; Forsyth PA
    Mol Ther; 2010 Nov; 18(11):1927-36. PubMed ID: 20808290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of novel oncolytic vaccinia virus with improved intravenous efficacy through protection against complement-mediated lysis and evasion of neutralization by vaccinia virus-specific antibodies.
    Lee N; Jeon YH; Yoo J; Shin SK; Lee S; Park MJ; Jung BJ; Hong YK; Lee DS; Oh K
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36717184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.